Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P. Lièvre A, et al. Among authors: landi b. J Clin Oncol. 2008 Jan 20;26(3):374-9. doi: 10.1200/JCO.2007.12.5906. J Clin Oncol. 2008. PMID: 18202412
Cetuximab efficacy in patients treated routinely in university hospitals.
Bachet JB, Afchain P, Fermanian C, Bouchahda M, Mitry E, Landi B, André T, Lièvre A, Louvet C, Aegerter P, Levi F, Rougier P. Bachet JB, et al. Among authors: landi b. Gastroenterol Clin Biol. 2007 Nov;31(11):941-9. doi: 10.1016/s0399-8320(07)78302-1. Gastroenterol Clin Biol. 2007. PMID: 18166882 Free article.
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F. Laurent-Puig P, et al. Among authors: landi b. J Clin Oncol. 2009 Dec 10;27(35):5924-30. doi: 10.1200/JCO.2008.21.6796. Epub 2009 Nov 2. J Clin Oncol. 2009. PMID: 19884556
Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.
Manceau G, Imbeaud S, Thiébaut R, Liébaert F, Fontaine K, Rousseau F, Génin B, Le Corre D, Didelot A, Vincent M, Bachet JB, Chibaudel B, Bouché O, Landi B, Bibeau F, Leroy K, Penault-Llorca F, Van Laethem JL, Demetter P, Tejpar S, Rossi S, Mosakhani N, Osterlund P, Ristamäki R, Sarhadi V, Knuutila S, Boige V, André T, Laurent-Puig P. Manceau G, et al. Among authors: landi b. Clin Cancer Res. 2014 Jun 15;20(12):3338-47. doi: 10.1158/1078-0432.CCR-13-2750. Epub 2014 Apr 25. Clin Cancer Res. 2014. PMID: 24771647
Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.
Laurent-Puig P, Pekin D, Normand C, Kotsopoulos SK, Nizard P, Perez-Toralla K, Rowell R, Olson J, Srinivasan P, Le Corre D, Hor T, El Harrak Z, Li X, Link DR, Bouché O, Emile JF, Landi B, Boige V, Hutchison JB, Taly V. Laurent-Puig P, et al. Among authors: landi b. Clin Cancer Res. 2015 Mar 1;21(5):1087-97. doi: 10.1158/1078-0432.CCR-14-0983. Epub 2014 Sep 23. Clin Cancer Res. 2015. PMID: 25248381
Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L, Bouché O, Normand C, Didelot A, Mulot C, Le Corre D, Garrigou S, Djadi-Prat J, Wang-Renault SF, Perez-Toralla K, Pekin D, Poulet G, Landi B, Taieb J, Selvy M, Emile JF, Lecomte T, Blons H, Chatellier G, Link DR, Taly V, Laurent-Puig P. Benhaim L, et al. Among authors: landi b. Eur J Cancer. 2021 Dec;159:24-33. doi: 10.1016/j.ejca.2021.09.004. Epub 2021 Oct 30. Eur J Cancer. 2021. PMID: 34731746
148 results